<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-7JIVHT3Y</identifier><date>2015</date><creator>Janežič, Matej</creator><creator>Perdih, Andrej</creator><creator>Pogorelčnik, Barbara</creator><relation>documents/doc/7/URN_NBN_SI_doc-7JIVHT3Y_001.pdf</relation><relation>documents/doc/7/URN_NBN_SI_doc-7JIVHT3Y_001.txt</relation><format format_type="issue">4</format><format format_type="volume">66</format><format format_type="type">article</format><format format_type="extent">str. 326-333</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">5768474</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-7JIVHT3Y</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="eng">DNA</subject><subject language_type_id="slv">encimi</subject><subject language_type_id="slv">farmacija</subject><subject language_type_id="slv">inhibitorji</subject><subject language_type_id="slv">molekularno modeliranje</subject><subject language_type_id="eng">pharmacy</subject><title>Inhibitors of DNA topoisomerase II alpha - an important target of anticancer therapy</title><title>Zaviralci DNA topoizomeraze II alfa - pomembne tarče protirakavih učinkovin</title></Record>